Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) EBITDA (2018 - 2025)

Historic EBITDA for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to -$20.7 million.

  • Precision Biosciences' EBITDA rose 285.78% to -$20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.5 million, marking a year-over-year decrease of 45227.69%. This contributed to the annual value of -$26.2 million for FY2024, which is 4018.2% up from last year.
  • According to the latest figures from Q3 2025, Precision Biosciences' EBITDA is -$20.7 million, which was up 285.78% from -$21.9 million recorded in Q2 2025.
  • Precision Biosciences' EBITDA's 5-year high stood at $24.1 million during Q2 2024, with a 5-year trough of -$30.7 million in Q4 2021.
  • In the last 5 years, Precision Biosciences' EBITDA had a median value of -$14.9 million in 2023 and averaged -$13.6 million.
  • In the last 5 years, Precision Biosciences' EBITDA skyrocketed by 87168.42% in 2024 and then crashed by 42811.08% in 2025.
  • Quarter analysis of 5 years shows Precision Biosciences' EBITDA stood at -$30.7 million in 2021, then surged by 60.59% to -$12.1 million in 2022, then decreased by 22.97% to -$14.9 million in 2023, then tumbled by 66.86% to -$24.8 million in 2024, then increased by 16.82% to -$20.7 million in 2025.
  • Its EBITDA stands at -$20.7 million for Q3 2025, versus -$21.9 million for Q2 2025 and -$22.1 million for Q1 2025.